Breaking News, Trials & Filings

Galena Tests Ovarian Cancer Vaccine

Phase I results positive

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Galena Biopharma presented Phase I data at a poster presentation at the Society for Immunotherapy of Cancer (SITC) Conference 2013 on November 7-10, 2013. The data presented are the results of the Phase I portion of the trial for the Folate Binding Protein (FBP) vaccine. FBP is a folate receptor alpha-derived, peptide-based cancer immunotherapy administered to HLA A2 positive patients in combination with granulocyte macrophage-colony stimulating factor (GM-CSF) as an adjuvant treatment to preven...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters